Holen Sie sich die Stockscreener-App
3.05
2.87%
-0.09
Vorhandelsmarkt:
2.95
-0.10
-3.28%
Schlusskurs vom Vortag:
$3.14
Offen:
$3.13
24-Stunden-Volumen:
583.12K
Relative Volume:
0.83
Marktkapitalisierung:
$302.49M
Einnahmen:
$69.56M
Nettoeinkommen (Verlust:
$-240.05M
KGV:
-1.0339
EPS:
-2.95
Netto-Cashflow:
$-121.90M
1W Leistung:
-6.15%
1M Leistung:
+10.11%
6M Leistung:
+79.41%
1J Leistung:
-16.21%
1-Tages-Spanne:
$2.98
$3.17
1-Wochen-Bereich:
$2.98
$3.33
52-Wochen-Spanne:
$1.05
$3.9823
Adc Therapeutics Sa Stock (ADCT) Company Profile
Firmenname
Adc Therapeutics Sa
Sektor
Branche
Telefon
41 21 653 02 00
Adresse
BIOPOLE, EPALINGES
Vergleichen Sie ADCT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADCT
Adc Therapeutics Sa
|
3.05 | 364.85M | 69.56M | -240.05M | -121.90M | -2.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Adc Therapeutics Sa Stock (ADCT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-08 | Eingeleitet | Stephens | Overweight |
| 2024-05-30 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-03-28 | Eingeleitet | Guggenheim | Buy |
| 2023-08-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-04-24 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-12-06 | Eingeleitet | CapitalOne | Overweight |
| 2022-11-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-09-21 | Eingeleitet | JP Morgan | Overweight |
| 2022-09-09 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-11-09 | Eingeleitet | Wolfe Research | Outperform |
| 2021-08-17 | Fortgesetzt | Jefferies | Buy |
| 2021-08-09 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-06-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-12-03 | Eingeleitet | Stifel | Hold |
| 2020-10-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-06-09 | Eingeleitet | BofA/Merrill | Buy |
| 2020-06-09 | Eingeleitet | Cowen | Outperform |
Alle ansehen
Adc Therapeutics Sa Aktie (ADCT) Neueste Nachrichten
ADC Therapeutics SA Stock Analysis and ForecastExplosive portfolio gains - jammulinksnews.com
What analysts say about ADC Therapeutics SA stockDynamic investment growth - jammulinksnews.com
Is ADC Therapeutics SA a good long term investmentTremendous portfolio expansion - Autocar Professional
What drives ADC Therapeutics SA stock priceBreakout stock performance - Autocar Professional
ADC Therapeutics’ LOTIS-10 Study: A Potential Game-Changer in Lymphoma Treatment - TipRanks
What makes ADC Therapeutics SA stock price move sharplyCapital Growth Picks - Newser
Why ADC Therapeutics SA stock attracts strong analyst attentionFree Market Sentiment Analysis - Newser
How ADC Therapeutics SA stock performs during market volatilityFree Exclusive Stock Market Insights - Newser
ADC Therapeutics (NYSE:ADCT) Shares Down 4.2%What's Next? - MarketBeat
Adc Therapeutics Sa shares fall 1.88% after-hours as Sonnet Biotherapeutics, Inc. announces $888 million funding. - AInvest
ADC Therapeutics (NYSE:ADCT) Shares Down 4.2% – Here’s Why - Defense World
ADC Therapeutics announces $100M private financing - MSN
ADC Therapeutics Makes Grant to New Employee Under Inducement Plan - The Malaysian Reserve
ADC Therapeutics (ADCT) Files Prospectus for Share Sale - GuruFocus
ADCT SEC FilingsAdc Therapeutics Sa 10-K, 10-Q, 8-K Forms - Stock Titan
The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough? - Weekly Voice
ADC reports data from lymphoma trial, streamlines operations - MSN
ADC Therapeutics (NYSE:ADCT) Stock Rating Upgraded by Royal Bank Of Canada - MarketBeat
ADC Therapeutics (ADCT) Price Target Lowered by RBC Capital | AD - GuruFocus
ADC Therapeutics price target lowered to $5 at RBC on growth outlook - Investing.com
ADC Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes - Quantisnow
Adc Therapeutics SA (NYSE: ADCT) Continues Its Downward Trend - Stocksregister
ADC Therapeutics Announces Updated ZYNLONTA Investigator-Initiated Trial Data in R/R Marginal Zone Lymphoma Presented at 18th International Conference on Malignant Lymphoma - marketscreener.com
ZYNLONTA shows 85% response rate in marginal zone lymphoma trial By Investing.com - Investing.com Nigeria
ZYNLONTA shows 85% response rate in marginal zone lymphoma trial - Investing.com Australia
Breakthrough Lymphoma Treatment: ZYNLONTA Shows 85% Response Rate with 27-Month Durability in Latest Trial - Stock Titan
Switzerland: ADC Therapeutics raises US$100m from PIPE financing - Investors in Healthcare
Guggenheim Reaffirms Buy Rating for ADC Therapeutics (NYSE:ADCT) - Defense World
ADC Therapeutics (NYSE:ADCT) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World
Analysts Set Expectations for ADCT FY2026 Earnings - MarketBeat
Guggenheim Raises Price Target for ADC Therapeutics (ADCT) | ADCT Stock News - GuruFocus
ADC Therapeutics (ADCT) Price Target Raised Amid Strategic Moves - GuruFocus
ADC Therapeutics (ADCT) Secures $100M in PIPE Financing to Boost ZYNLONTA Development - GuruFocus
Layoff Tracker: ADC Therapeutics Cutting 30% of Staff, Closing London Research Facility - BioSpace
ADC Therapeutics (NYSE:ADCT) Price Target Raised to $10.00 at Guggenheim - MarketBeat
ADC Therapeutics price target raised to $10 from $7 on positive trial data By Investing.com - Investing.com South Africa
ADC Therapeutics price target raised to $10 from $7 on positive trial data - Investing.com India
ADC Therapeutics (ADCT) Price Target Raised Amid Strategic Moves | ADCT Stock News - GuruFocus
Finanzdaten der Adc Therapeutics Sa-Aktie (ADCT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):